Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net loss	$ (133,978)	$ (37,938)	$ (102,519)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	14,951	16,551	14,881
Stock-based compensation	18,885	17,399	10,326
Impairment of long-lived assets	0	12,576	0
Other non-cash transactions	1,359	198	(657)
Changes in assets and liabilities:
Accounts receivable	20,164	(20,301)	6,034
Inventory	(5,390)	(795)	2,848
Other assets	(12,267)	577	(200)
Accounts payable	(3,384)	4,274	(8,046)
Accrued compensation	3,555	(800)	(1,518)
Accrued expenses	1,013	1,683	(4,191)
Accrued clinical trial expenses	(191)	(2,023)	(3,455)
Deferred revenue	(17,516)	(47,025)	126,795
Other liabilities	(943)	(247)	(559)
Net cash (used in) provided by operating activities	(113,742)	(55,871)	39,739
Cash flows from investing activities:
Purchases of property and equipment	(9,722)	(31,457)	(16,390)
Advance payments for property and equipment			(4,312)
Maturities of investments	383,052	475,813	310,707
Sales of investments	210,089	15,479	17,318
Purchases of investments	(695,371)	(443,122)	(451,918)
Transaction costs for sale of pulmonary assets			(4,440)
Net cash (used in) provided by investing activities	(111,952)	16,713	(149,035)
Cash flows from financing activities:
Issuance of common stock, net of issuance costs	224,313	8,891	4,820
Payments of loan and capital lease obligations	(1,978)	(1,356)	(1,285)
Net cash provided by financing activities	222,335	7,535	3,535
Effect of exchange rates on cash and cash equivalents	916	(219)	(226)
Net decrease in cash and cash equivalents	(2,443)	(31,842)	(105,987)
Cash and cash equivalents at beginning of year	17,755	49,597	155,584
Cash and cash equivalents at end of year	15,312	17,755	49,597
Supplemental disclosure of cash flows information:
Cash paid for interest	10,277	10,599	11,225
Cash paid for income taxes	957	407	743
Supplemental schedule of non-cash investing and financing activities:
Property and equipment acquired through capital leases		$ 195